Palbociclib plus letrozole as treatment for postmenopausal women with hormone receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer for whom letrozole therapy is deemed appropriate: An expanded access study in Australia and India

Sherene Loi1 | Christos S. Karapetis2 | Nicole McCarthy3 | Catherine Oakman4 | Andrew Redfern5 | Michelle White6 | Mustafa Khasraw7 | Dinesh Chandra Doval8 | Vinod Gore9 | Mahmood Alam10 | Justin Binko10 | Dongrui Ray Lu11 | Sindy Kim11 | Frances Boyle12

1 Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
2 Flinders Medical Centre and Flinders University, Adelaide, Australia
3 Icon Cancer Centre Wesley, Auchenflower, Queensland, Australia
4 Sunshine Hospital, Victoria, Australia
5 Fiona Stanley Hospital, Murdoch, Australia
6 Monash Health, Clayton, Victoria, Australia
7 Duke Cancer Institute, Durham, North Carolina, USA
8 Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India
9 Sahyadri Super Specialty Hospital, Pune, Maharashtra, India
10 Pfizer Australia, Sydney, Australia
11 Pfizer Inc, San Diego, California, USA
12 Patricia Ritchie Centre for Cancer Care and Research, Mater Hospital, North Sydney, Australia

Abstract

Aim: Palbociclib was approved in the United States in 2015 to treat estrogen receptor–positive/human epidermal growth factor receptor 2–negative (HER2–) advanced breast cancer (ABC). This study evaluated outcomes and safety in patients treated with palbociclib in Australia and India with hormone receptor–positive (HR+)/HER2– ABC before palbociclib became commercially available.

Methods: Postmenopausal women (≥18 years) with HR+/HER2– ABC who were appropriate candidates for letrozole therapy received palbociclib 125 mg once daily for 21 days followed by 7 days off, and letrozole 2.5 mg once daily (continuous). Safety, tumor response, and patient-reported outcomes (Australian cohort) were evaluated.

Results: In total, 252 patients received palbociclib plus letrozole (Australia, n = 152; India, n = 100). More patients in the Australian versus Indian cohort had received prior chemotherapy (advanced/metastatic setting: 45.9% vs. 32.0%), endocrine therapy (advanced/metastatic setting: 63.2% vs. 54.3%), and advanced/metastatic therapies (61.8% vs. 31.0%). The most frequently reported all-grade palbociclib-related treatment-emergent adverse events were neutropenia (66.7%), fatigue (35.3%), and stomatitis (26.6%); grade 3/4 neutropenia was reported as palbociclib-related in 62.7% of patients. Febrile neutropenia was reported in six patients (2.4%). Eight patients (3.2%) discontinued because of an adverse event. The objective response rate was 19.4% (95% CI, 14.7%–24.9%) overall and 2.3% in Australian patients with ≥2 lines of prior therapy for metastatic disease. Patient-reported quality of life scores were maintained throughout the study.

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

© 2021 The Authors. Asia-Pacific Journal of Clinical Oncology published by John Wiley & Sons Australia, Ltd
1 | INTRODUCTION

Globally, breast cancer is the most commonly diagnosed cancer among women. In 2018, Australia/New Zealand had the highest incidence rate of breast cancer worldwide, whereas in India, breast cancer was the leading cause of cancer death among women. Historically, endocrine monotherapy has been the preferred first-line treatment option for postmenopausal women with estrogen receptor–positive (ER+)/human epidermal growth factor receptor 2–negative (HER2–) advanced breast cancer (ABC). The first-in-class cyclin-dependent kinase 4/6 (CDK4/6) inhibitor, palbociclib, in combination with letrozole was initially approved in 2015 in the United States for the treatment of ER+/HER2– ABC. Results from the PALOMA clinical trials showed a statistically significant improvement in median progression-free survival (PFS) with palbociclib plus letrozole compared with letrozole alone (PALOMA-1R): 20.2 vs. 10.2 months; hazard ratio = 0.488 [95% CI, 0.319–0.748], P = 0.0004) or placebo plus letrozole (PALOMA-2R: 27.6 vs. 14.5 months; hazard ratio = 0.56 [95% CI, 0.46–0.69], P < 0.0001) in postmenopausal women with ER+/HER2– ABC. The PALOMA-3 trial demonstrated the benefit of palbociclib plus fulvestrant compared with placebo plus fulvestrant (median PFS, 11.2 vs. 4.6 months; hazard ratio = 0.50 [95% CI, 0.40–0.62]; P < 0.0001) in pre-/postmenopausal women with hormone receptor–positive (HR+)/HER2– ABC who had disease progression following endocrine therapy. The most frequently reported adverse event (AE) with palbociclib was neutropenia in all three PALOMA trials. Quality of life was also maintained with the addition of palbociclib to either letrozole or fulvestrant treatment.

As a result of recent advances in targeted therapies, the National Comprehensive Cancer Network category 1, Cancer Australia, and European Society for Medical Oncology international consensus guidelines for ABC now recommend the addition of a CDK4/6 inhibitor to endocrine therapy as a preferred treatment regimen for premenopausal and postmenopausal women with HR+/HER2– ABC. However, the safety and efficacy of medications may differ across various patient subgroups based on factors such as race or ethnicity. The primary objective of this expanded access program study was to evaluate the safety of palbociclib plus letrozole in patients with HR+/HER2– ABC for whom letrozole therapy was deemed appropriate in Australia and India before palbociclib became commercially available. In addition, antitumor activity of palbociclib was assessed. Patient-reported outcomes (PROs) were also collected for the Australian cohort.

2 | METHODS

2.1 | Study design

This was an open-label, single-arm, multinational, multicenter (20 sites) clinical trial providing access to palbociclib in Australia and India for patients with HR+/HER2– ABC who were deemed appropriate candidates for letrozole therapy (NCT02679755). The study protocol was approved by the Institutional Review Boards and/or Independent Ethics Committee at each of the participating study sites. The study was conducted in compliance with the Declaration of Helsinki, Good Clinical Practice guidelines, and local country regulations relevant to the use of new therapeutic agents. All patients provided written and informed consent.

Key inclusion criteria included postmenopausal women, defined as per local practice, aged ≥18 years with HR+/HER2– ABC and an Eastern Cooperative Oncology Group (ECOG) performance status score of 0–2 who were deemed appropriate candidates for letrozole therapy. These broad entry criteria led to the enrollment of many patients who were heavily pretreated in the metastatic disease setting in Australia. To ensure appropriate patients were enrolled in the study, the inclusion criteria was amended to specify “in the first-line advanced/metastatic setting.” Key exclusion criteria included prior treatment with any CDK inhibitor, previous participation in a palbociclib clinical trial, and active uncontrolled or symptomatic brain metastases.

Patients received palbociclib orally once daily at 125 mg for 3 weeks followed by 1 week off treatment for each 4-week cycle (3/1 schedule). Commercially available letrozole was administered orally at 2.5 mg once daily on a continuous daily dosing schedule according to product labeling and in compliance with local prescribing information. Patients continued to receive palbociclib and letrozole until disease progression, symptomatic deterioration, unacceptable toxicity, death, or withdrawal of consent, whichever occurred first.

2.2 | Outcomes

The primary endpoint was safety. AEs were characterized by type, frequency, severity (as graded by the National Cancer Institute
Common Terminology Criteria for Adverse Events version 4.03), and seriousness. All AEs reported after the initiation of palbociclib were considered treatment-emergent AEs (TEAEs). All AEs were coded by System Organ Class and preferred term (PT) using the Medical Dictionary for Regulatory Activities coding, with cluster terms used as noted in the table footnotes. Hematology was performed at screening, on Days 1 and 14 of the first two cycles, and then on Day 1 of each subsequent cycle, and was recorded in the case report form (CRF). Blood chemistry was performed at screening and per routine clinical practice thereafter; blood chemistry data were collected at screening only.

Secondary endpoints included tumor response (based on investigator assessment per local practice) and PRO of health-related quality of life and health status. Tumor assessments were performed at screening and per routine clinical practice according to the patients’ clinical status. The investigators’ assessments were reported on the CRFs. The best tumor response was the best outcome the patient had out of all the tumor assessments during the study as assessed by the local investigator; investigators were not required to use Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Duration of treatment was calculated as the length of time patients remained on palbociclib treatment from the first day of treatment until the last day of treatment in this study, regardless of the reason for discontinuation.

Patient-reported outcomes of health-related quality of life and health status were assessed using the European Quality of Life-5 Dimensions (EQ-5D) instrument in Australian patients only. Patients completed the EQ-5D questionnaire at predose at Cycle 1/Day 1, at every clinical visit thereafter, and at the end of study. Progression-free survival (PFS) and overall survival (OS) were not included in the study objectives; therefore, these data were not collected.

2.3 | Statistical analyses

Approximately 300 patients from Australia and India were to be enrolled in this study. The as-treated (AT) population or safety analysis set included all patients who received ≥1 dose of palbociclib. The PRO-evaluable population was defined as patients from the AT population who completed the EQ-5D at baseline and ≥1 visit after baseline.

Tumor assessments were performed at screening and per local practice. No uniform assessment schedule was planned for patients across the sites. As an expanded access program study, no inferential analyses were planned, and no hypotheses were tested. The objective response (OR) rate and the corresponding exact 95% two-sided confidence interval (CI) were calculated using standard methods based on the binomial distribution. A descriptive summary of treatment duration (mean, median, range) was generated.

The EQ-5D index was derived by combining one level from each of the five dimensions and converting it to a single summary index or health utility value, a higher score indicating better quality of life/well-being. For patients from Australia, analysis of PROs used descriptive statistics for the actual score and change from baseline for the EQ-5D index and EQ-5D visual analog scale (VAS) scores. The mean (95% CI), median (range), and number of patients completing the scale at each time assessment after baseline were summarized.

3 | RESULTS

3.1 | Patients

A total of 252 patients were enrolled in the study at 20 sites across Australia and India. In Australia, a total of 152 patients were enrolled beginning in March 2016 to January 2018; in India, 100 patients were enrolled beginning in March 2017 to June 2018. All enrolled patients received palbociclib and letrozole and were included in the AT population for safety analysis (Figure S1).

Patient demographics and baseline disease characteristics are included in Table 1. The median age was 58 years (range, 30–83 years), and 29.4% of patients were aged ≥65 years. Demographic characteristics were generally similar between the Australian and Indian cohorts, with the exception of the proportion of White and Asian patients. In the overall population, 75% of patients had ductal carcinoma, whereas 15.9% had lobular carcinoma. Ductal carcinoma was less common in the Australian cohort relative to the Indian cohort (67.8% vs. 86.0%, respectively). Prior treatment for metastatic disease was more frequent in the Australian cohort compared with patients from India (61.8% vs. 31.0%, including prior chemotherapy [45.9% vs. 32.0%], and prior endocrine therapy [63.2% vs. 54.3%]). More patients in the Australian cohort (n = 17; 18.1%) were heavily pretreated (>3 prior therapies in the metastatic disease setting) compared with patients in the Indian cohort (n = 0; Table S1). At the conclusion of the study, a total of 139 (55.2%) patients discontinued from the study (Australian cohort, n = 105; Indian cohort, n = 34); 107 patients (42.5%) had discontinued because of disease progression, 8 patients (3.2%) discontinued because of AEs, and 113 patients (44.8%) were considered to have ”completed” the study after transitioning to commercially available palbociclib once it became commercially available in each country.

3.2 | Adverse events

The median durations of treatment were 12 months (range, <1.0–35.7) for palbociclib and 12.3 months (range, <1 to 39.5) for letrozole. A total of 60 patients (23.8%) had one palbociclib dose reduction, and 31 patients (12.3%) had two dose reductions. Palbociclib dose interruptions due to AEs were reported in 187 patients (74.2%).

In the Australian cohort, the median durations of treatment for palbociclib and letrozole were 13.6 months (range, <1.0–35.7) and 13.8 months (<1.0–35.9), respectively. In the Indian cohort, the median durations of treatment were 10.7 months (range, <1.0–22.2) and 10.9 months (range, <1.0–22.4), respectively. More patients in the Australian cohort reported ≥1 palbociclib dose reduction than in the Indian cohort (48.7% vs. 17.0%, respectively), reflecting a more heavily pretreated population. In the subgroup of patients in the Australian cohort who received ≥2 lines of prior metastatic therapies (n = 43),
### TABLE 1  Patient demographic and baseline characteristics

| Characteristic | Palbociclib + Letrozole Australian Cohort (n = 152) | Palbociclib + Letrozole Indian Cohort (n = 100) | Palbociclib + Letrozole Total Cohort (N = 252) |
|---------------|--------------------------------------------------|---------------------------------|---------------------------------|
| Age, years    | Median (range)                                   | 58 (34–83)                      | 58 (30–79)                      | 58 (30–83)                      |
|               | Age group, years                                 |                                 |                                 |                                 |
| 18–44         | 27 (17.8)                                        | 13 (13.0)                       | 40 (15.9)                       |
| 45–64         | 80 (52.6)                                        | 58 (58.0)                       | 138 (54.8)                      |
| ≥65           | 45 (29.6)                                        | 29 (29.0)                       | 74 (29.4)                       |
| Race          | White                                            | 130 (85.5)                      | 0 (0.0)                         | 130 (51.6)                      |
|               | Black                                            | 1 (0.7)                         | 0 (0.0)                         | 1 (0.4)                         |
|               | Asian                                            | 12 (7.9)                        | 100 (100.0)                     | 112 (44.4)                      |
|               | Other                                            | 9 (5.9)                         | 0 (0.0)                         | 9 (3.6)                         |
| ECOG PS       | 0                                                | 86 (56.6)                       | 38 (38.0)                       | 124 (49.2)                      |
|               | 1                                                | 60 (39.5)                       | 60 (60.0)                       | 120 (47.6)                      |
|               | 2                                                | 6 (3.9)                         | 2 (2.0)                         | 8 (3.2)                         |
| ER+           | 152 (100)                                        | 100 (100)                       | 252 (100)                       |
| PR+           | 115 (75.7)                                       | 88 (88.0)                       | 203 (80.6)                      |
| Histopathological classification |                                         |                                 |                                 |                                 |
| Ductal carcinoma | 103 (67.8)                                     | 86 (86.0)                       | 189 (75.0)                      |
| Lobular carcinoma | 32 (21.1)                                      | 8 (8.0)                         | 40 (15.9)                       |
| Unknown       | 5 (3.3)                                          | 6 (6.0)                         | 11 (4.4)                        |
| Other         | 12 (7.9)                                         | 0 (0.0)                         | 12 (4.8)                        |
| Duration of breast cancer since histopathological diagnosis, years |                                         |                                 |                                 |                                 |
| Median (range) | 5.8 (0.0–32.0)                                 | 0.7 (0.0–17.0)                  | 3.6 (0.0–32.0)                  |
| Prior surgeries | 123 (80.9)                                     | 57 (57.0)                       | 180 (71.4)                      |
| Prior radiation therapies | 117 (77.0)                                   | 52 (52.0)                       | 169 (67.1)                      |
| Prior systemic therapies | 139 (91.4)                                  | 61 (61.0)                       | 200 (79.4)                      |
| Prior metastatic therapies | 94 (61.8)                                    | 31 (31.0)                       | 125 (49.6)                      |
| No. of regimens |                                         |                                 |                                 |                                 |
| 1             | 51 (54.3)                                        | 25 (80.6)                       | 76 (60.8)                       |
| 2             | 16 (17.0)                                        | 6 (19.4)                        | 22 (17.6)                       |
| 3             | 10 (10.6)                                        | 0 (0.0)                         | 10 (8.0)                        |
| > 3           | 17 (18.1)                                        | 0 (0.0)                         | 17 (13.6)                       |
| Prior chemotherapyb |                                        |                                 |                                 |                                 |
| Neoadjuvant   | 14 (12.8)                                        | 7 (14.0)                        | 21 (13.2)                       |
| Adjuvant      | 78 (71.6)                                        | 34 (68.0)                       | 112 (70.4)                      |
| Advanced/metastatic | 50 (45.9)                                    | 16 (32.0)                       | 66 (41.5)                       |
| Prior endocrine therapy† | 125 (82.2)                                 | 35 (35.0)                       | 160 (63.5)                      |
| Aromatase inhibitor | 101 (80.8)                                 | 25 (71.4)                       | 126 (78.8)                      |
| Fulvestrant   | 9 (7.2)                                          | 0 (0.0)                         | 9 (5.6)                         |
| Tamoxifen     | 78 (62.4)                                        | 14 (40.0)                       | 92 (57.5)                       |

(Continues)
In patients who received ≥ 2 lines of prior therapy for metastatic disease in the Australian cohort, all-causality AEs were reported in all 43 patients; grade 3 or 4 AEs were reported in 37 patients (86.0%), and SAEs in 17 patients (39.5%; Table S3). Forty patients (93.0%) in this subgroup reported a palbociclib-related AEs, with grade 3 or 4 AEs reported in 34 patients (79.1%) and SAEs in 7 patients (16.3%); 2 patients (4.7%) permanently discontinued palbociclib because of an AE.

The most frequently reported all-causality TEAEs in the AT population were neutropenia (65.7%), infection (49.6%), fatigue (42.9%), and stomatitis (31.3%; Table S4). The most frequently reported palbociclib-related TEAEs were neutropenia (66.7%), fatigue (35.3%), and stomatitis (26.6%; Table 3). Neutropenia was reported as a palbociclib-related grade 3 or 4 TEAE in 158 patients (62.7%) in the AT population and in 102 (67.1%) and 56 (56%) patients in the Australian and Indian cohorts, respectively. There were no reports of all-causality or palbociclib-related lymphopenia. Among patients in the Australian cohort who received ≥ 2 lines of therapy in the metastatic setting, neutropenia (74.4%), infections (53.5%), and fatigue (51.2%) were the most frequently reported all-causality TEAEs, whereas neutropenia (74.4%) and fatigue (44.2%) were the most frequently reported palbociclib-related AEs (Supplementary Table S5). Palbociclib-related grade 3 or 4 neutropenia was reported in 31 patients (72.1%).

A total of 91 patients (36.1%) had a dose reduction for palbociclib due to an AE; the most frequently reported AEs associated with dose reduction (in ≥ 2% of patients) were neutropenia (31.7%) and infections (2.4%). In the Indian cohort, 14 patients (14%) had a dose reduction due to neutropenia compared with 66 patients (43.4%) in the Australian cohort. A total of 188 patients (74.6%) had a dose reduction for palbociclib and/or letrozole due to an AE; the most frequently reported AEs associated with dose interruption (in ≥ 5% of patients) were neutropenia (60.3%), infections (13.9%), leukopenia (6.0%), and thrombocytopenia (5.2%). Eight patients (3.2%) were permanently discontinued from the study because of AEs, five (2.0%) of whom discontinued due to a palbociclib-related AE (one patient each: headache, liver function test increased, malaise, neutropenia, and pneumonitis [grade 2; considered palbociclib-related by investigator]).

A total of 63 patients experienced all-causality SAEs; the most frequently reported (≥ 3% of patients) were infections (7.5%) and disease progression (3.2%). Palbociclib-related SAEs were reported in 20 patients (7.9%); the most frequently reported SAEs (≥ 2% of patients)
TABLE 3  Palbociclib-related treatment-emergent AEs that occurred in ≥10% of patients (AT population)

| Adverse event      | Palbociclib + Letrozole (N = 252) | Grade 1 | Grade 2 | Grade 3 | Grade 4 | All grades |
|--------------------|----------------------------------|---------|---------|---------|---------|------------|
| Patients with any AE | 27 (10.7)                       | 24 (9.5)| 142 (56.3)| 29 (11.5)| 223 (88.5)|            |
| Neutropenia        | 0 (0.0)                          | 10 (4.0)| 131 (52.0)| 27 (10.7)| 168 (66.7)|            |
| Fatigue            | 66 (26.2)                        | 22 (8.7)| 1 (0.4) | 0 (0.0) | 89 (35.3) |            |
| Stomatitis         | 52 (20.6)                        | 13 (5.2)| 2 (0.8) | 0 (0.0) | 67 (26.6) |            |
| Alopecia           | 37 (14.7)                        | 0 (0.0)| 0 (0.0) | 0 (0.0) | 37 (14.7) |            |
| Diarrhea           | 24 (9.5)                         | 8 (3.2)| 4 (1.6) | 0 (0.0) | 36 (14.3) |            |
| Nausea             | 33 (13.1)                        | 3 (1.2)| 0 (0.0) | 0 (0.0) | 36 (14.3) |            |
| Infections         | 17 (6.7)                         | 9 (3.6)| 8 (3.2) | 0 (0.0) | 34 (13.5) |            |
| Anemia             | 1 (0.4)                          | 9 (3.6)| 17 (6.7)| 0 (0.0) | 27 (10.7) |            |
| Thrombocytopenia   | 5 (2.0)                          | 11 (4.4)| 8 (3.2)| 3 (1.2) | 27 (10.7) |            |

Abbreviations: AE, adverse event; AT, as-treated; MedDRA, Medical Dictionary for Regulatory Activities coding.

Note. All values are presented as n (%). Included data up to 28 days after last dose of study drug. Palbociclib-related was defined as AE causality assessed by investigator as “Yes, related” or “Unknown.”

*Neutropenia includes the following MedDRA preferred terms: neutropenia and neutrophil count decreased.

*Stomatitis includes the following MedDRA preferred terms: aphthous stomatitis, cheilitis or glossitis, glossodynia, mouth ulceration, mucosal inflammation, oral pain, oropharyngeal discomfort, oropharyngeal pain, and stomatitis.

*Infections includes the following MedDRA preferred terms: any event having a Preferred Term part of the System Organ Class Infections and infestations.

*Anemia includes the following MedDRA preferred terms: anemia, hematocrit decreased, and hemoglobin decreased.

*Thrombocytopenia includes the following MedDRA preferred terms: Platelet count decreased and thrombocytopenia.

were febrile neutropenia (2.4%) and infections (2.0%). A total of 10 on-study deaths occurred (up to 28 days after the last dose of study drug). Eight patients died from disease progression, including three patients who died during the study treatment period, one died following an increased liver function test of unknown cause (considered palbociclib-related by the investigator), and one from multiple organ dysfunction syndrome due to an underlying condition.

3.3 | Laboratory parameters

The most frequent grade 3 hematology abnormalities observed were reduction in absolute neutrophils (52.8% of patients) and white blood cells (39.7% of patients; Table 5). Grade 4 abnormalities included reduced absolute neutrophils (11.1% of patients), reduced platelets (2.0% of patients), and reduced white blood cells (1.6% of patients). Shifts from baseline grade ≤2 to postbaseline grade 3 and grade 4 for reduced absolute neutrophils were reported for 52.8% and 11.1% of patients, respectively. A shift from baseline grade ≤2 to postbaseline grade 3 anemia was reported for 8.7% of patients. There were no significant reports of lymphopenia.

3.4 | Best overall tumor response

The observed OR rate (based on investigator assessment) was 19.4% (95% CI, 14.7–24.9) for the total population, including three patients with complete response (Table 4). In the India cohort, the OR rate was 29.0% (95% CI, 20.4–38.9), and in the Australia cohort, OR rate was 13.2% (95% CI, 8.2–19.6). Australian patients with ≥2 lines of prior therapy for metastatic disease (n = 43) had an observed OR rate of 2.3%; a best response of partial response was reported in one patient; stable disease was reported in 22 patients (51.2%), and 16 patients (37.2%) had progressive disease.

3.5 | Patient-reported health-related quality of life

A total of 146 patients (96.1%) in the Australia cohort were included in the PRO-evaluable population. The percentage of patients completing ≥1 question on the EQ-5D from Cycle 1 to Cycle 38 ranged from 90.9% to 100.0% (AT population). The percentages of patients on treatment who completed ≥1 question on the survey at 6 months and 1 year were 99% and 100%, respectively. Change from baseline in EQ-5D health utility index score and in EQ-5D VAS score showed that general and overall health status, respectively, were maintained during treatment with palbociclib plus letrozole (Figure 1).

4 | DISCUSSION

This expanded access program study showed that palbociclib plus letrozole was generally well tolerated in postmenopausal women with HR+/HER2− ABC in Australia and India for whom letrozole therapy...
FIGURE 1 Change from baseline in (A) EQ-5D Health Utility Index Score and (B) EQ-5D Visual Analog Scale Score (PRO-evaluable population). EQ-5D, European Quality of Life-5 Dimensions; PRO, patient-reported outcome; SE, standard error.
was deemed appropriate. The observed OR in the total population was 19.4%. AEs were consistent with the known safety profile of palbociclib plus letrozole. Neutropenia was the most frequently reported palbociclib-related grade 3/4 TEAE. Although neutropenia was nearly universal, fever and infection were uncommon, supporting a different mechanism underlying the development of neutropenia compared with that caused by chemotherapy, with more rapid recovery upon withdrawal of palbociclib. Overall quality of life was maintained with palbociclib treatment. As this was an expanded access protocol, PFS and OS data were not included in the study objectives; thus, these data were not collected.

Of note, patient enrollment in India began 1 year after Australia, and palbociclib became commercially available earlier in India than in Australia. Therefore, Australian patients had a longer duration of treatment with palbociclib than Indian patients (13.6 and 10.7 months, respectively), likely due to Indian patients coming off the study to receive the commercially available drug.

The observed OR rates were 13.2% and 29.0% in the Australian and Indian cohorts, respectively. The lower OR rate for the Australian cohort was likely due to the higher number of patients in this cohort who received prior systemic treatment in the metastatic disease setting compared with the Indian cohort; including 28.3% of patients who received >1 line of therapy for metastatic disease. Moreover, many of the women in the Australian cohort had been treated with endocrine therapy before receiving palbociclib combination therapy in this study (63.2%); 54.3% of women in the Indian cohort had received prior endocrine therapy in the metastatic disease setting. Australian patients who had received ≥2 lines of prior therapy for metastatic disease had an observed OR rate of 2.3%; thus, patients who received more extensive systemic treatment in the advanced/metastatic setting before study enrollment likely contributed to the OR rate in the total Australian cohort. In the Indian cohort, 69.0% of patients had de novo metastatic disease, compared with only 38.2% of patients in the Australian cohort. The difference in the number of previous lines of metastatic therapy by country is due to an inclusion criterion amendment to only include patients who would be receiving first-line treatment for ABC, which was issued approximately 3 months after enrollment began in Australia (and may have taken even longer to implement due to timing of local IRB approvals), and before enrollment was initiated in India. Before this amendment, many heavily pretreated patients in Australia were enrolled in this study. Approximately 52% of all patients (Australian cohort, 63.2%; Indian cohort, 34.0%) reported a best response of stable disease, which is important because stable disease is associated with patient quality of life. However, unlike the PALOMA clinical studies where RECIST criteria were utilized, tumor assessments in this study were performed according to investigator assessment per local practice.

An ad hoc subgroup analysis of Australian patients who received ≥2 lines of prior therapy in the metastatic disease setting showed, not surprisingly, that the median duration of on-study treatment with palbociclib was shorter compared with the total cohort (5.9 months vs. 12.0 months, respectively). However, to our knowledge this represents the only data with palbociclib and letrozole in a heavily pretreated patient population, suggesting that some of these patients derived clinical benefit. Similar to the total cohort, approximately 5.0% of patients with ≥2 lines of prior therapy in the Australian subgroup discontinued palbociclib because of an AE, albeit a higher percentage of patients reported palbociclib-related neutropenia compared with the total combined population (74.4% vs. 66.7%, respectively), as well as grade 3/4 neutropenia (72.1% vs. 62.7%).

Results from this study are consistent with and add to the current body of literature supporting the safety of palbociclib. Similar to observations from the PALOMA-1 and PALOMA-2 clinical trials, the most common all-causality AEs reported with palbociclib plus letrozole in this study included neutropenia and fatigue; the percentage of patients who experienced all-causality grade 3/4 neutropenia was also similar to those percentages observed in PALOMA-1 and -2 (62.7% vs. 54.2% and 66.4%, respectively; Australian cohort, 67.1%; Indian cohort, 56.0%). Moreover, in this study and in PALOMA-1 and -2, disease progression was the primary reason for permanent discontinuation, and a similar percentage of patients receiving palbociclib reported a dose reduction (36.1% vs. 40.0% and 36.0%, respectively).

### Table 4: Best overall tumor responseat (AT population)

| Response                  | Palbociclib + Letrozole Australian Cohort (n = 152) | Palbociclib + Letrozole Indian Cohort (n = 100) | Palbociclib + Letrozole Total Cohort (N = 252) |
|---------------------------|---------------------------------------------------|------------------------------------------------|-----------------------------------------------|
| Complete response         | 2 (1.3)                                           | 1 (1.0)                                        | 3 (1.2)                                       |
| Partial response          | 18 (11.8)                                         | 28 (28.0)                                      | 46 (18.3)                                     |
| Stable/no response        | 96 (63.2)                                         | 34 (34.0)                                      | 130 (51.6)                                    |
| Objective progression     | 30 (19.7)                                         | 20 (20.0)                                      | 50 (19.8)                                     |
| Indeterminate response    | 6 (3.9)                                           | 17 (17.0)                                      | 23 (9.1)                                      |
| Objective responseb       | 20 (13.2)                                         | 29 (29.0)                                      | 49 (19.4)                                     |
| 95% exact CI              | 8.2–19.6                                          | 20.4–38.9                                      | 14.7–24.9                                     |

Abbreviation: AT, as-treated.
Note. All values are presented as n (%).

as assessed by investigator.
bComplete response plus partial response.
Of note, the observed OR rate was lower in this study than observed with palbociclib treatment in PALOMA-1 and PALOMA-2 (19.4% vs. 43.0% and 42.1%, respectively). Maintaining patients’ quality of life is an important goal of therapy, as ABC can have a long natural history. Consistent with previous analyses of PALOMA-2, this study showed that palbociclib plus letrozole did not compromise patients’ quality of life.

In contrast with this study, patients included in PALOMA-1 and PALOMA-2 were not eligible for enrollment if they received previous systemic treatment for ABC. This difference may explain the lower OR observed in this study compared with the first-line PALOMA studies, as this study initially enrolled patients who were considered appropriate candidates for letrozole therapy per investigator assessment. Other differences in the patient population between these studies include that patients were younger in this study than those enrolled in PALOMA-1 and -2 who received palbociclib plus letrozole (median, 58 years vs. 63 years and 62 years, respectively). A higher percentage of patients in this study were also treated with prior neoadjuvant or adjuvant chemotherapy compared with patients receiving palbociclib in PALOMA-1 and PALOMA-2 (52.8% vs. 40.0% and 48.0%, respectively); 41.5% of patients in this study received prior chemotherapy for metastatic breast cancer. Despite these differences, the safety profile of palbociclib plus letrozole among Australian and Indian patients was similar to first-line palbociclib clinical trials and we did not observe any differences that can be attributed to ethnicity.

5 | CONCLUSIONS

In postmenopausal women with HR+/HER2− ABC in Australia and India who were deemed appropriate for letrozole therapy, palbociclib plus letrozole was generally well tolerated and manageable, with a safety profile consistent with previous observations. More patients in the Australian versus the Indian cohort had received prior chemotherapy, endocrine therapy, and advanced/metastatic therapies. The observed OR rates based on investigator assessment were 19.4% (95% CI, 14.7–24.9) in the overall population and 29.0% and 13.2% in the India and Australia cohorts, respectively. Overall, patient-reported general health status was maintained during study treatment.

ACKNOWLEDGMENTS

The authors would like to thank all of the patients and their families as well as all study investigators, research coordinators, and site staff. Editorial support was provided by Jill Shults, PhD, of ICON plc (North Wales, PA, USA), and funded by Pfizer Inc. S. Loi was supported by the National Breast Cancer Foundation of Australia Endowed Chair and the Breast Cancer Research Foundation, New York.

DATA AVAILABILITY STATEMENT

Upon request, and subject to certain criteria, conditions, and exceptions (see https://www.pfizer.com/science/clinical-trials/trial-data-and-results for more information), Pfizer will provide access to individual de-identified participant data from Pfizer-sponsored global interventional clinical studies conducted for medicines, vaccines, and medical devices (1) for indications that have been approved in the US and/or EU or (2) in programs that have been terminated (i.e., development for all indications has been discontinued). Pfizer will also consider requests for the protocol, data dictionary, and statistical analysis plan. Data may be requested from Pfizer trials 24 months after study completion. The de-identified participant data will be made available to researchers whose proposals meet the research criteria and other conditions, and for which an exception does not apply, via a secure portal. To gain access, data requestors must enter into a data access agreement with Pfizer.

FUNDING

This study was sponsored by Pfizer Inc.

DISCLOSURES

Sherene Loi receives research funding to her institution from Novartis, Bristol Myers Squibb, Merck, Roche-Genentech, Puma Biotechnology, Pfizer, Eli Lilly, and Seattle Genetics; has acted as consultant (not compensated) to Seattle Genetics, Pfizer, Novartis, Bristol Myers Squibb, Merck, AstraZeneca, and Roche-Genentech; and has acted as consultant (paid to her institution) to Aduro Biotech, Novartis, and G1 Therapeutics. Nicole McCarthy has acted as a consultant for Pfizer, Novartis, Roche, Eli Lilly, and Eisai. Andrew Redfern has acted as a consultant to Pfizer, AstraZeneca, Novartis, Roche, and Eisai (paid to his research institution). Michelle White has acted as a consultant for Novartis, Eisai, Pfizer, AstraZeneca, and Roche. Mustafa Khasraw reports consultant or advisory roles for Janssen, AbbVie, Ipsen, Pfizer, Roche, and Jackson Laboratory for Genomic Medicine; and research funding from AbbVie, Bristol Myers Squibb, and Specialized Therapeutics. Frances Boyle has acted as a consultant to Pfizer, AstraZeneca, Novartis, Eli Lilly, Roche, and Eisai (paid to her practice). Christos S. Karapetis, Catherine Oakman, Dinesh Chandra Doval, and Vinod Gore have no conflicts of interest to disclose. Mahmoud Alam, Justin Binko, Dongrui Ray Lu, and Sindy Kim are employees of and own stock in Pfizer Inc.

ORCID

Sherene Loi https://orcid.org/0000-0001-6137-9171

REFERENCES

1. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.
2. Cardoso F, Senkus E, Costa A, et al. 4th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 4). Ann Oncol. 2018;29:1634–1657.
3. Beaver JA, Amiri-Kordestani L, Charlab R, et al. FDA approval: Palbociclib for the treatment of postmenopausal patients with estrogen receptor-positive, HER2-negative metastatic breast cancer. Clin Cancer Res. 2015;21:4760–4766.
4. IBRANCE® capsules (palbociclib). Full Prescribing Information, Pfizer Inc, New York, NY, 2019.
5. Finn RS, Crown JP, Lang I, et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive,
HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): A randomised phase 2 study. Lancet Oncol. 2015;16:25-35.

6. Rugo HS, Finn RS, Dieras V, et al. Palbociclib plus letrozole as first-line therapy in estrogen receptor–positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up. Breast Cancer Res Treat. 2019;174:719-729.

7. Finn RS, Martin M, Rugo HS, et al. Palbociclib and letrozole in advanced breast cancer. N Engl J Med. 2016;375:1925-1936.

8. Cristofanilli M, DeMichele A, Giorgetti C, et al. Predictors of prolonged benefit from palbociclib plus fulvestrant in women with endocrine-resistant hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer in PALOMA-3. Eur J Cancer. 2018;104:21-31.

9. Turner NC, Ro J, Andre F, et al. Palbociclib in hormone-receptor–positive advanced breast cancer. N Engl J Med. 2015;373:209-219.

10. Gradishar WJ, Anderson BO, Abraham J, et al. Breast cancer, version 3.2020, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2020;18:452-478.

11. Cancer Australia Statements – Influencing best practice in cancer care. Available at: https://thestatement.canceraustralia.gov.au/metastatic Accessed November 5, 2020.

12. Clark LT, Watkins L, Pina IL, et al. Increasing diversity in clinical trials: Overcoming critical barriers. Curr Probl Cardiol. 2019;44:148-172.

13. Rugo HS, Dieras V, Gelmon KA, et al. Impact of palbociclib plus letrozole on patient-reported health-related quality of life: Results from the PALOMA-2 trial. Ann Oncol. 2018;29:888-894.

SUPPORTING INFORMATION
Additional supporting information may be found online in the Supporting Information section at the end of the article.

How to cite this article: Loi S, Karapetis CS, McCarthy N, et al. Palbociclib plus letrozole as treatment for postmenopausal women with hormone receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer for whom letrozole therapy is deemed appropriate: An expanded access study in Australia and India. Asia-Pac J Clin Oncol. 2022;18:560–569. https://doi.org/10.1111/ajco.13653